

Curriculum Vitae Christoph Otto

Personal Data

Title	Prof. Dr. rer. nat.
First name	Christoph
Name	Otto
Current position	Extraordinary Professor (APL, permanent)
Current institution(s)/site(s), country	Faculty of Medicine, Julius-Maximilians-Universität Würzburg (JMU Würzburg), University Hospital Würzburg (UKW), Dept. of General, Visceral, Transplant, Vascular and Pediatric Surgery Experimental Visceral Surgery, Germany
Identifiers/ORCID	0009-0004-7203-7803

Selection of peer-reviewed research articles:

1. Kollmann C, Buerkert H, Meir M, *et int*, **Otto C**, Burkard N, Schlegel N. Human organoids are superior to cell culture models for intestinal barrier research. *Front Cell Dev Biol.* 2023 Oct 2;11:1223032. doi: 10.3389/fcell.2023.1223032.
2. **Otto C**, Kastner C, Schmidt S, *et int*, Wiegering A. RNA polymerase I inhibition induces terminal differentiation, growth arrest and vulnerability to senolytics in colorectal cancer cells. *Mol Oncol.* 2022 Jun 8. doi: 10.1002/1878-0261.13265.
3. Burkard N, Meir M, Kannapin F, **Otto C**, *et int*, Schlegel N. Desmoglein2 Regulates Claudin2 Expression by Sequestering PI-3-Kinase in Intestinal Epithelial Cells. *Front Immunol.* 2021 Sep 30;12:756321. doi: 10.3389/fimmu.2021.756321.
4. Dischinger U, Heckel T, Bischler T, *et int*, **Otto C**, *et int*, Hankir MK. Roux-en-Y Gastric Bypass and Caloric Restriction but Not Gut Hormone-Based Treatments Profoundly Impact the Hypothalamic Transcriptome in Obese Rats. *Nutrients.* 2021 Dec 28;14(1):116. doi: 10.3390/nu14010116.
5. Dischinger U, Hasinger J, Königsrainer M, Corteville C, **Otto C**, *et int*, Seyfried FJD. Toward a Medical Gastric Bypass: Chronic Feeding Studies With Liraglutide + PYY₃₋₃₆ Combination Therapy in Diet-Induced Obese Rats. *Front Endocrinol (Lausanne).* 2021 Jan 22;11:598843. doi: 10.3389/fendo.2020.598843.
6. Hankir MK, Rotzinger L, Nordbeck A, *et int*, **Otto C**, Seyfried F. Leptin Receptors Are Not Required for Roux-en-Y Gastric Bypass Surgery to Normalize Energy and Glucose Homeostasis in Rats. *Nutrients.* 2021 Mai 4;13(5):1544. doi: 10.3390/nu13051544.
7. **Otto C**, Friedrich A, Vrhovac Madunić I, *et int*, Koepsell H. Antidiabetic Effects of a Tripeptide That Decreases Abundance of Na⁺-d-glucose Cotransporter SGLT1 in the Brush-Border Membrane of the Small Intestine. *ACS Omega.* 2020 Nov 4;5(45):29127-29139. doi: 10.1021/acsomega.0c03844.
8. **Otto C**, Friedrich A, Vrhovac Madunić I, *et int*, Koepsell H. Antidiabetic Effects of a Tripeptide That Decreases Abundance of Na⁺-d-glucose Cotransporter SGLT1 in the Brush-Border Membrane of the Small Intestine. *ACS Omega.* 2020 Nov 4;5(45):29127-29139. doi: 10.1021/acsomega.0c03844.
9. **Otto C**, Schmidt S, Kastner C, *et int*, Wiegering A. Targeting bromodomain-containing protein 4 (BRD4) inhibits MYC expression in colorectal cancer cells. *Neoplasia.* 2019 Nov;21(11):1110-1120. doi: 10.1016/j.neo.2019.10.003.
10. Schmidt S, Gay D, Uthe FW, *et int*, **Otto C**, *et int*, Wiegering A. A MYC-GCN2-eIF2 α negative feedback loop limits protein synthesis to prevent MYC-dependent apoptosis in colorectal cancer. *Nat Cell Biol.* 2019 Nov;21(11):1413-1424. doi: 10.1038/s41556-019-0408-0.